Mass. Firm to Appeal $431M Damages for Stent Patent Infringement
A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
- First Brands Judge Approves Examiner to Probe Fraud Allegations
- The Return Period for An LA Wildfire-Scale Event May Be Shorter Than You Think
- Allianz Built An AI Agent to Train Claims Professionals in Virtual Reality
- NYC Sues Delivery App Over Lost Pay in New Mamdani Crackdown
- Marijuana’s Move to Schedule III: What it Really Means for Cannabis Insurance
- Severity Was up, But How Will Falling Claims Volume Impact The Profession?
- Nationwide Spending $100M on AI to Beef up Claims Efficiency, Customer Experience
- Billionaire NFL Owner Suing Over Billboards Near His SoFi Stadium